AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26551364 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour of PVSSC
Number of subjects: 39
Study 22964452 — intervention group
Group type: EXPERIMENTAL
Intervention: 6mg/kg anhydrous caffeine fasted
Number of subjects: 14
Study 22964452 — intervention group
Group type: EXPERIMENTAL
Intervention: 9mg/kg anhydrous caffeine fasted
Number of subjects: 14
Study 22964452 — intervention group
Group type: COMPARATOR
Intervention: 6mg/kg anhydrous caffeine fed
Number of subjects: 14
Study 22964452 — intervention group
Group type: COMPARATOR
Intervention: 9mg/kg anhydrous caffeine fed
Number of subjects: 14
Study 21978872 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB-converted patients
Number of subjects: 2203
Study 21978872 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective OPCAB conversions
Number of subjects: 2203
Study 19203715 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 microg Se/day)
Number of subjects: 179
Study 19203715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 16965415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin plus hydrocortisone butyrate ointment
Number of subjects: 327
Study 16965415 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment plus hydrocortisone butyrate ointment
Number of subjects: 327
Study 15373933 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW) 900 mg day(‐1) for 14 days
Number of subjects: 13
Study 15373933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15373933 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW)
Number of subjects: 13
Study 15373933 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam
Number of subjects: 13
Study 11318297 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 30
Study 11318297 — intervention group
Group type: COMPARATOR
Intervention: pilocarpine 4%
Number of subjects: 30
Study 9253329 — intervention group
Group type: COMPARATOR
Intervention: GH alone (0.3 IU/kg.day)
Number of subjects: 24
Study 9253329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IGF‐I (80 micrograms/kg.day) and GH (0.3 IU/kg.day)
Number of subjects: 24
Study 9253329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8323473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with dipyridamole (75 mg three times a day) and aspirin (330 mg three times a day)
Number of subjects: 2500
Study 8323473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 3103983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined blunt spatula debridement and trifluridine therapy
Number of subjects: 31
Study 3103983 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine alone
Number of subjects: 31
Study 31693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐Based Participatory Research intervention (4-week duration)
Number of subjects: 39
Study 31693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐Based Participatory Research intervention
Number of subjects: 39
Study 31693994 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 39
Study 30496408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 0
Study 27929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 75
Study 27929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 75
Study 27929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 75
Study 27929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses)
Number of subjects: 75
Study 27929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 75
Study 27929674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 25985246 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-001 (8 units, 1.5 × 10^6 cells per unit) in phase 1b study
Number of subjects: 50
Study 25985246 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-001 (1 unit or 4 units, 2 infusions 1 week apart) in phase 2a study
Number of subjects: 50
Study 25985246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25985246 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-001 (1 unit or 4 units)
Number of subjects: 50
Study 24330604 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application intervention for physical activity adherence
Number of subjects: 40
Study 24330604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (physical activity and educational advice)
Number of subjects: 40
Study 24330604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 40
Study 21224289 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion
Number of subjects: 13
Study 19202720 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive behavioral condition
Number of subjects: 60
Study 19202720 — intervention group
Group type: COMPARATOR
Intervention: Health-based education (control) condition
Number of subjects: 60
Study 17062470 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with chest shield
Number of subjects: 54
Study 17062470 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy without chest shield
Number of subjects: 54
Study 16036075 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11885184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated grooved implants
Number of subjects: 149
Study 11885184 — intervention group
Group type: COMPARATOR
Intervention: Preoperative antibiotics
Number of subjects: 149
Study 11885184 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant length
Number of subjects: 149
Study 11885184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean stability values (PTVs)
Number of subjects: 149
Study 8738691 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat
Number of subjects: 45
Study 8738691 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat
Number of subjects: 45
Study 8738691 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-injured patients (HI)
Number of subjects: 45
Study 8738691 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 45
Study 1540597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (30 mg three times daily increasing to 60 mg three times daily at 1 month)
Number of subjects: 69
Study 1540597 — intervention group
Group type: COMPARATOR
Intervention: No calcium blocker (Control)
Number of subjects: 69
Study 4048359 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/kg)
Number of subjects: 7
Study 4048359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28641469 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (6 group sessions, twice per week for 3 weeks)
Number of subjects: 152
Study 28641469 — intervention group
Group type: COMPARATOR
Intervention: Control (no counselling)
Number of subjects: 152
Study 26794922 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwich Patellar Instability (NPI) Score
Number of subjects: 50
Study 22377774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mahjong
Number of subjects: 36
Study 22377774 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 36
Study 22377774 — intervention group
Group type: COMPARATOR
Intervention: Handicrafts (placebo)
Number of subjects: 36
Study 20374034 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant aromatase inhibitors (AI) for 3 months
Number of subjects: 14
Study 17826268 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS mini‐incision mid‐vastus (mini)
Number of subjects: 90
Study 17826268 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS side‐cutting (side cut)
Number of subjects: 90
Study 17826268 — intervention group
Group type: COMPARATOR
Intervention: Conventional (control)
Number of subjects: 90
Study 16062074 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 14
Study 16062074 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 14
Study 16062074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m2 every 21 days
Number of subjects: 14
Study 16062074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable, as the phase II part was canceled)
Number of subjects: 14
Study 11863244 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 19
Study 11863244 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19
Study 12370869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 39
Study 12370869 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 9791043 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral analysis method
Number of subjects: 26
Study 9791043 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva method
Number of subjects: 26
Study 9791043 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine method
Number of subjects: 26
Study 7997500 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed partial subperiosteal implants
Number of subjects: 52
Study 7997500 — intervention group
Group type: COMPARATOR
Intervention: Classical design partial subperiosteal implants
Number of subjects: 52
Study 3137024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 3137024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31200668 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy from a psychiatric nurse
Number of subjects: 450
Study 31200668 — intervention group
Group type: COMPARATOR
Intervention: Non-specific support given by volunteers
Number of subjects: 450
Study 31200668 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 450
Study 29798368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection of budesonide (BUD) 0.5 mg/ml
Number of subjects: 180
Study 29798368 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic injection of dexamethasone (DEX) 5 mg/ml
Number of subjects: 180
Study 29798368 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NS) solution (1 ml)
Number of subjects: 180
Study 25100232 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants informed at encoding of the context in which cues were to appear
Number of subjects: 0
Study 25100232 — intervention group
Group type: COMPARATOR
Intervention: Participants not informed at encoding of the context
Number of subjects: 0
Study 25100232 — intervention group
Group type: EXPERIMENTAL
Intervention: Task interference during the third phase with specified cue context
Number of subjects: 0
Study 25100232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Gaussian parameter estimates
Number of subjects: 0
Study 22939855 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior cavopulmonary anastomosis
Number of subjects: 193
Study 22939855 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at superior cavopulmonary anastomosis
Number of subjects: 193
Study 22939855 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 193
Study 22939855 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior cavopulmonary anastomosis type, valve regurgitation, ventricular ejection fraction, and ventricular end-diastolic pressure
Number of subjects: 193
Study 21977965 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg once daily
Number of subjects: 170
Study 18326612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg Zn as zinc sulfate
Number of subjects: 631
Study 18326612 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg Zn as zinc sulfate
Number of subjects: 631
Study 18326612 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Zn as zinc sulfate
Number of subjects: 631
Study 18326612 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Zn + 0.5 mg Cu as copper sulfate
Number of subjects: 631
Study 18326612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 17726807 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin (3 mg Drospirenone and 30 microg ethinylestradiol)
Number of subjects: 0
Study 17726807 — intervention group
Group type: COMPARATOR
Intervention: Meliane (75 microg gestodene + 20 microg ethinylestradiol)
Number of subjects: 0
Study 17726807 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin and Meliane
Number of subjects: 0
Study 14638387 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide and co‐enzyme Q(10)
Number of subjects: 19
Study 14638387 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 10883875 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+Metro (subgingival scaling and root planing with metronidazole 25% dental gel)
Number of subjects: 59
Study 10883875 — intervention group
Group type: COMPARATOR
Intervention: SRP (subgingival scaling and root planing without metronidazole)
Number of subjects: 59
Study 8615309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium scintigraphy measuring left ventricular cavity size
Number of subjects: 335
Study 8615309 — intervention group
Group type: COMPARATOR
Intervention: Normal perfusion patterns
Number of subjects: 335
Study 1426202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Number of subjects: 56
Study 1426202 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilator therapy alone (salbutamol or ipratropium bromide)
Number of subjects: 56
Study 31200648 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interventions (specific types not detailed) in Study 1
Number of subjects: 1389
Study 31200648 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interventions (specific types not detailed) in Study 2
Number of subjects: 1389
Study 31200648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in both studies
Number of subjects: 1389
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with daily activities
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes knowledge
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in daily activities
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose
Number of subjects: 81
Study 30295170 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 81
Study 26381427 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron and dexamethasone (low-risk patients)
Number of subjects: 152
Study 26381427 — intervention group
Group type: EXPERIMENTAL
Intervention: aprepitant, extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Number of subjects: 152
Study 26381427 — intervention group
Group type: EXPERIMENTAL
Intervention: extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Number of subjects: 152
Study 26381427 — intervention group
Group type: COMPARATOR
Intervention: Control group (level 0)
Number of subjects: 152
Study 25038148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) infusion during dynamic handgrip exercise (15% maximal effort)
Number of subjects: 39
Study 25038148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) infusion
Number of subjects: 39
Study 22799481 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 121
Study 22799481 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 121
Study 19588075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with diode laser (Laser White 10, Biolase) with a diode laser (810 nm, 10 W) activation
Number of subjects: 40
Study 19588075 — intervention group
Group type: COMPARATOR
Intervention: Bleaching without light activation (Opalescence Xtra Boost, Ultradent)
Number of subjects: 40
Study 19588075 — intervention group
Group type: COMPARATOR
Intervention: Bleaching treatment with a plasma arc lamp (Remewhite, Remedent)
Number of subjects: 40
Study 19588075 — intervention group
Group type: COMPARATOR
Intervention: Bleaching with a light emitting diode (LED) lamp (By White accelerator, Ensodent)
Number of subjects: 40
Study 17287387 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of diabetes
Number of subjects: 197
Study 17287387 — intervention group
Group type: COMPARATOR
Intervention: No evidence of diabetes
Number of subjects: 197
Study 16060742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0
Study 16060742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience with compatibility of career and children made salient
Number of subjects: 0
Study 12392343 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive static magnetic field (SMF)
Number of subjects: 75
Study 12392343 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative static magnetic field (SMF)
Number of subjects: 75
Study 12392343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no SMF)
Number of subjects: 75
Study 10593670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 134
Study 10593670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 134
Study 10593670 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 134
Study 7503851 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 14.5 micrograms/kg
Number of subjects: 40
Study 7503851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1.0 mg/kg
Number of subjects: 40
Study 7503851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2248839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 69
Study 7025778 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (N = 88)
Number of subjects: 118
Study 7025778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 30)
Number of subjects: 118
Study 7025778 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (N = 61, continued therapy in open trial)
Number of subjects: 118
Study 30599109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound of the hands
Number of subjects: 51
Study 30599109 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS 28 VS
Number of subjects: 51
Study 30599109 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS 28 CRP
Number of subjects: 51
Study 30599109 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAI
Number of subjects: 51
Study 29030584 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional objects (TOs)
Number of subjects: 16
Study 29030584 — intervention group
Group type: COMPARATOR
Intervention: Familiar objects (FOs)
Number of subjects: 16
Study 29030584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar objects (UOs)
Number of subjects: 16
Study 26207520 — intervention group
Group type: EXPERIMENTAL
Intervention: Television advertisement (TVC)
Number of subjects: 384
Study 26207520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advertisement)
Number of subjects: 384
Study 24813099 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 360
Study 24813099 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 360
Study 21442459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (once-yearly intravenous dose)
Number of subjects: 600
Study 21442459 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (once-weekly oral dose)
Number of subjects: 600
Study 19896879 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary nursing interventions
Number of subjects: 0
Study 19896879 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the institution
Number of subjects: 0
Study 17550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 348
Study 17550361 — intervention group
Group type: COMPARATOR
Intervention: Written Feedback (WF)
Number of subjects: 348
Study 17550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 348
Study 14686964 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg candesartan cilexetil
Number of subjects: 74
Study 14686964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11848327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A (6 mg/kg body weight in divided doses for six months)
Number of subjects: 23
Study 11848327 — intervention group
Group type: COMPARATOR
Intervention: Stanozolol (1 mg/kg body weight/day in divided doses)
Number of subjects: 23
Study 10091204 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464
Study 10091204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit D (300 IU/day and 100 IU/day during the fifth year)
Number of subjects: 464
Study 10091204 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Vit D
Number of subjects: 464
Study 10091204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 7818958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 223
Study 7818958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 29
Study 3391874 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 29